Esketamine on Postpartum Depression in Cesarean Section Women

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study was to explore the preventive effect of esketamine on postpartum depression in cesarean section, and to evaluate the safety of the drug

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ailin Luo
• Collaborators: Central South University; Dalian Municipal Central Hospital; First Affiliated Hospital of Guangxi Medical University; Guangdong Women and Children Hospital; Maternal and Child Health Hospital of Hubei Province; Shandong Jining No.1 People's Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of University of South China; Third Affiliated Hospital of Zhengzhou University
• Treatments: Esketamine

Criteria

Inclusion Criteria:

• Elective cesarean section;

• 18-40 years;

• Primipara;

• Singleton pregnancy;

• Sign informed consent.

Exclusion Criteria:

• ASA grade III and above;

• Intracranial hypertension;

• Hypertension;

• Severe heart disease;

• Hyperthyroidism patients without treatment or insufficient treatment;

• Liver and kidney dysfunction;

• Preeclampsia or eclampsia;

• Mental disorder, mental retardation;

• Drug abuse and alcoholism;

• Contraindication of intraspinal anesthesia;

• The preoperative EPDS score ≥10;

• Participated in other clinical studies.